Tandem Diabetes Care (NSDQ:TNDM) today shared real-world data on its t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology.
Presenting at the 14th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD), the company touted immediate and sustained improvements in time-in-range (TIR) observed in more than 9,000 people with diabetes using the system for 12 months.
San Diego-based Tandem reported glycemic trends in type 1 diabetes patients based on their time of adoption of the t:slim X2 insulin pump with Control-IQ technology. A study sample included 6,233 people with type 1 diabetes who initiated use of the technology between its launch on Jan. 15, 2020, and July 15, 2020. That population was divided into three groups — those who adopted within four weeks of launch (Group A), between three and four months (B) and five and six months (C).
Regardless of which group participants fell into, Tandem reported that all groups experienced significant improvements in sensor TIR, according to a news release.
The company also reported on a study sample of diverse groups of people with type 1 diabetes with 700 participants who uploaded at least 21 days of pump data to Tandem’s web application and had at least 75% CGM use during this period. Among that group, TIR measured a 72.5% median, while quality of life survey measures showed significant reductions in diabetes impact and greater satisfaction with Control-IQ technology compared to previous insulin delivery devices.
A presentation of outcomes from 12 consecutive months of real-world Control-IQ use reported a median TIR of 73.6%, marking an increase of 10% from the baseline measurement. The median percent time in automation or “closed-loop” came in at 94.2%, while the median percent time below 70 mg/dL hit approximately 1%.
Tandem also reported on real-world analysis of more than 72,000 individuals using Control-IQ, with a significant improvement demonstrated in nighttime glycemic control. Patient-reported outcomes also confirmed a decrease in diabetes burden and an increase in device satisfaction.
“Experience matters in automated insulin dosing systems, and Control-IQ technology is performing as well in the real world as it did in the pivotal studies,” Tandem Diabetes Care medical director Dr. Jordan Pinsker said in the news release. “Additionally, patient-reported outcomes, including reduced diabetes burden and improved sleep quality, demonstrate that our Control-IQ technology can make a positive and sustained impact on the lives of people with diabetes.”
